Literature DB >> 14991488

Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection.

Harvey G Moore1, Alicia E Gittleman, Bruce D Minsky, Douglas Wong, Philip B Paty, Martin Weiser, Larissa Temple, Leonard Saltz, Jinru Shia, Jose G Guillem.   

Abstract

INTRODUCTION: Recent data suggest a favorable prognosis for rectal cancer patients with a pathologic complete response to preoperative combined modality therapy. Prolongation of the interval between preoperative combined modality therapy and surgery (RT-surgery interval) as a means of increasing pathologic complete response rate has not been fully examined.
METHODS: One hundred and fifty-five rectal cancer patients undergoing preoperative pelvic external beam radiation therapy and 5-fluorouracil-based chemotherapy followed by rectal resection were identified. All patients had endorectal ultrasound prior to combined modality therapy. Final pathology reports were reviewed for ypT and ypN stage and margin status. Medical records were reviewed for sphincter preservation, operative time, estimated blood loss, hospital stay, and morbidity (overall, anastomotic, and perineal).
RESULTS: A pathologic complete response (ypT0N0) occurred in 24 patients (15 percent). Median RT-surgery interval was 44 (range, 15-206) days. A pathologic complete response occurred in 19 percent of patients with an interval >44 days, vs. 12 percent in those with an interval < or =44 days ( P = 0.27). Downstaging by three stages occurred more frequently in the long-interval group (15 percent vs. 6 percent, P = 0.11). The rates of sphincter preservation, positive margins, estimated blood loss, and operative time were not significantly different. Overall morbidity was similar between groups.
CONCLUSIONS: Our results demonstrate a trend toward increased pathologic complete response rate and downstaging with increased RT-surgery interval. However, sphincter preservation is not increased. Until prospective analyses are conducted assessing the impact of prolonged RT-surgery interval on long-term outcome, the benefit of a prolonged interval between the completion of preoperative combined modality therapy and surgery remains unclear.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991488     DOI: 10.1007/s10350-003-0062-1

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  81 in total

1.  Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation.

Authors:  Eric Sorenson; Fernando Lambreton; Jian Q Yu; Tianyu Li; Crystal S Denlinger; Joshua E Meyer; Elin R Sigurdson; Jeffrey M Farma
Journal:  J Surg Res       Date:  2019-06-21       Impact factor: 2.192

2.  Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.

Authors:  Julio Garcia-Aguilar; David D Smith; Karin Avila; Emily K Bergsland; Peiguo Chu; Richard M Krieg
Journal:  Ann Surg       Date:  2011-07       Impact factor: 12.969

3.  Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance.

Authors:  Dietrich Doll; Ralf Gertler; Matthias Maak; Jan Friederichs; Karen Becker; Hans Geinitz; Monika Kriner; Hjalmar Nekarda; Jörg R Siewert; Robert Rosenberg
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

4.  Signet ring cell histology and non-circumferential tumors predict pathological complete response following neoadjuvant chemoradiation in rectal cancers.

Authors:  Sunil Bhanu Jayanand; Ramakrishnan Ayloor Seshadri; Ritesh Tapkire
Journal:  Int J Colorectal Dis       Date:  2010-11-03       Impact factor: 2.571

5.  Usefulness of two independent histopathological classifications of tumor regression in patients with rectal cancer submitted to hyperfractionated pre-operative radiotherapy.

Authors:  Lukasz Liszka; Ewa Zielińska-Pajak; Jacek Pajak; Dariusz Gołka; Jacek Starzewski; Zbigniew Lorenc
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

6.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

7.  Re: Salvaging a linear staple line defect in ultra-low anterior resection.

Authors:  Y-H Ho
Journal:  Tech Coloproctol       Date:  2008-03       Impact factor: 3.781

Review 8.  Interval to surgery after neoadjuvant treatment for colorectal cancer.

Authors:  Nir Wasserberg
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

9.  Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Wladimir Nadalin; Jorge Sabbaga; Ulysses Ribeiro; Afonso Henrique Silva e Sousa; Fábio Guilherme Campos; Desidério Roberto Kiss; Joaquim Gama-Rodrigues
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

10.  Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer.

Authors:  Annefleur E M Berkel; Dankert P Woutersen; Job van der Palen; Joost M Klaase
Journal:  J Gastrointest Surg       Date:  2014-06-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.